Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DC-CIK cells
- Development stage
- Unknown
- Lead developer
- Shenzhen Hornetcorn Bio-technology
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
DC-CIK cells are an autologous cell-based immunotherapy consisting of dendritic cells (DCs) and cytokine-induced killer (CIK) cells. Developed by Shenzhen Hornetcorn Bio-technology Company, LTD, this therapy is designed to enhance the body's anti-tumor immune response. Dendritic cells are professional antigen-presenting cells that, when co-cultured with CIK cells, improve their proliferation and tumor-specific cytotoxicity. CIK cells are a unique population of T lymphocytes that express both T-cell (CD3) and natural killer (NK) cell (CD56) markers, allowing for potent, non-MHC-restricted lysis of malignant cells. In the context of hepatocellular carcinoma, these cells are often administered following Transcatheter Arterial Chemoembolization (TACE) to eliminate residual tumor cells and reduce the risk of recurrence.
- Other names
- Dendritic cell-cytokine induced killer cellsDC-CIKAutologous DC-CIK cells
02
Targets
NCR3LG1 (Natural cytotoxicity triggering receptor 3 ligand 1)MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on DC-CIK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DC-CIK cells.